Another micro-cap biotech has flunked a pivotal test for a regenerative cell therapy
Today the failure belongs to Cytori Therapeutics $CYTX which says that the cells it extracted from patients’ fat failed to hit either the primary or secondary endpoints in a Phase III comparison with placebo in treating scleroderma. Most of the endpoint scores were far off from any indication of success.
Shares of Cytori were eviscerated on the news, dropping 60% into penny stock land.
The San Diego-based biotech, though, was able to extract some material to back its therapy Habeo, even though investors were not in any way reassured.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
